Ann Intern Med:提高高血压筛查准确度需要解决的两个问题:筛查间隔和筛查后确诊方法

2015-02-24 梁怀彬 译 MedSci原创

高血压是心血管疾病死亡的最大风险因素,亦是最大的全因死亡风险因素。 为更新现有系统评价“提前识别高血压人群的利与弊”,总结现有的关于合适的筛查间隔时间、不同方法对高血压的诊断预测精准度的相关证据,研究者作了一项系统评估,近日发表在Ann Intern Med杂志上。 研究者收录相关的高质量诊断准确度比较,高血压人群检出方面的英语出版的研究文献。数据提取工作由一名调查员独自完成,另一名负责准确性校对

高血压是心血管疾病死亡的最大风险因素,亦是最大的全因死亡风险因素。 为更新现有系统评价“提前识别高血压人群的利与弊”,总结现有的关于合适的筛查间隔时间、不同方法对高血压的诊断预测精准度的相关证据,研究者作了一项系统评估,近日发表在Ann Intern Med杂志上。 研究者收录相关的高质量诊断准确度比较,高血压人群检出方面的英语出版的研究文献。数据提取工作由一名调查员独自完成,另一名负责准确性校对。此外还对研究质量进行双重评估。 数据合并后发现:不同研究里,24小时血压动态监测识别为高血压后,长期心血管结局危险比(1.28 to 1.40, in 11 studies),27项研究发现:35%-95%的新检出高血压人群在随后的隔段时间再确认测量时仍为高血压。筛查时为高血压经隔段时间再测量确认为血压正常人群的心血管结局风险和筛查时为正常血压的心血管结局风险无异。40项研究发现:筛检间隔时间从每年到每6年,不同间隔后再次筛检确认出来的高血压的发生率相差相当大。研究同时观察到:老年人、血压时而高时而正常的人群、超重及肥胖人群、以及非洲裔美国人有着至少两倍的高血压发生率。 研究者

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2056677, encodeId=d07520566e7e1, content=<a href='/topic/show?id=e20f312062d' target=_blank style='color:#2F92EE;'>#准确度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31206, encryptionId=e20f312062d, topicName=准确度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon May 25 20:46:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990464, encodeId=72321990464cd, content=<a href='/topic/show?id=fc69e59420d' target=_blank style='color:#2F92EE;'>#筛查间隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75942, encryptionId=fc69e59420d, topicName=筛查间隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat Sep 19 15:46:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606415, encodeId=43891606415c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 26 10:46:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17002, encodeId=97e01e002c0, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:49:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16941, encodeId=be3d16941d3, content=明了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Feb 24 23:32:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
    2015-05-25 zutt
  2. [GetPortalCommentsPageByObjectIdResponse(id=2056677, encodeId=d07520566e7e1, content=<a href='/topic/show?id=e20f312062d' target=_blank style='color:#2F92EE;'>#准确度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31206, encryptionId=e20f312062d, topicName=准确度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon May 25 20:46:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990464, encodeId=72321990464cd, content=<a href='/topic/show?id=fc69e59420d' target=_blank style='color:#2F92EE;'>#筛查间隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75942, encryptionId=fc69e59420d, topicName=筛查间隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat Sep 19 15:46:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606415, encodeId=43891606415c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 26 10:46:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17002, encodeId=97e01e002c0, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:49:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16941, encodeId=be3d16941d3, content=明了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Feb 24 23:32:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2056677, encodeId=d07520566e7e1, content=<a href='/topic/show?id=e20f312062d' target=_blank style='color:#2F92EE;'>#准确度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31206, encryptionId=e20f312062d, topicName=准确度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon May 25 20:46:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990464, encodeId=72321990464cd, content=<a href='/topic/show?id=fc69e59420d' target=_blank style='color:#2F92EE;'>#筛查间隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75942, encryptionId=fc69e59420d, topicName=筛查间隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat Sep 19 15:46:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606415, encodeId=43891606415c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 26 10:46:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17002, encodeId=97e01e002c0, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:49:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16941, encodeId=be3d16941d3, content=明了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Feb 24 23:32:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2056677, encodeId=d07520566e7e1, content=<a href='/topic/show?id=e20f312062d' target=_blank style='color:#2F92EE;'>#准确度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31206, encryptionId=e20f312062d, topicName=准确度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon May 25 20:46:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990464, encodeId=72321990464cd, content=<a href='/topic/show?id=fc69e59420d' target=_blank style='color:#2F92EE;'>#筛查间隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75942, encryptionId=fc69e59420d, topicName=筛查间隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat Sep 19 15:46:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606415, encodeId=43891606415c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 26 10:46:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17002, encodeId=97e01e002c0, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:49:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16941, encodeId=be3d16941d3, content=明了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Feb 24 23:32:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
    2015-02-25 orthoW

    不错的文章,学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2056677, encodeId=d07520566e7e1, content=<a href='/topic/show?id=e20f312062d' target=_blank style='color:#2F92EE;'>#准确度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31206, encryptionId=e20f312062d, topicName=准确度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon May 25 20:46:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990464, encodeId=72321990464cd, content=<a href='/topic/show?id=fc69e59420d' target=_blank style='color:#2F92EE;'>#筛查间隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75942, encryptionId=fc69e59420d, topicName=筛查间隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat Sep 19 15:46:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606415, encodeId=43891606415c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 26 10:46:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17002, encodeId=97e01e002c0, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:49:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16941, encodeId=be3d16941d3, content=明了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Tue Feb 24 23:32:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
    2015-02-24 hbwang006

    明了

    0

相关资讯

NEJM:妊娠期高血压疾病:尴尬的舒张压要不要控制?!

关于妊娠期高血压疾病是产科常见疾患,患病率约为10%。1%在怀孕前就存在高血压,即妊娠合并慢性高血压;5% - 6%有不伴蛋白尿的妊娠期高血压;2%为子痫前期。先前有研究表明妊娠合并慢性高血压和34周前妊娠期高血压会增加围生期并发症和孕产妇并发症风险。 目前临床上对于妊娠期伴有轻度高血压孕产妇血压管理目标仍有争议。因此Laura A. Magee等人进行了一项开放的、国际的、多中心的随机对照

LANCET:经皮硝酸甘油可有效控制急性卒中发作后高血压

卒中后高血压可能导致不良的转归,卒中后早期血压是否应该降低、是应该继续服用卒中前就已在服用的降压药物还是短暂撤除降压药这些问题一直争论不休,研究者为此开展实验评估中风后使用降压药对卒中后转归影响。在这项多中心的实验中,研究者将入院的急性缺血性脑卒中和出血性脑卒中的高血压患者(收缩压140-220mm Hg)一部分患者采用经皮硝酸甘油渗透连续7天(5mg每天)。均开始于中风发作后48h内。对照组不给

Stroke:女性摄入半胱氨酸及其他氨基酸量与卒中发生的关系

半胱氨酸可能会通过降血压、抗氧化作用降低卒中发生的风险。我们的目标是验证下列假设:半胱氨酸的摄入量与卒中的发生率成负相关。研究方法:我们采用了基于人群的瑞典乳房X线照相术队列的数据,该队列共有34250例女性,这些女性未患心血管疾病、癌症,并且在1997年秋天的进行了有关卒中的饮食和其他危险因素的食谱问卷调查。卒中病例由瑞典住院病人注册中心和瑞典死亡原因注册中心联合研究确定。利用COX比例风险回归

JAMA Intern Med:收缩压不高的养老院高龄老人降压需慎重

有充分的证据支持:身体素质较好的社区高龄(大于80岁)高血压人群降血压治疗会收益颇多,然而在一些围绕体质虚弱的的老年人观察性研究上,没有显示出降压治疗的优势,甚至出现了降压可能增加患病率、死亡率。 为评估养老院年龄大于80岁的老年人的全因死亡率和收缩压水平以及服用降压药量的关系,研究者开展了这项研究。这项纵向观察研究的观察群体是养老院的高龄老人,研究者分析了低收缩压(<130 mm Hg

NEJM:产前高血压是否需要严格控制?

《新英格兰医学杂志》近期发表了一项研究成果:产前严格控制高血压与非严格控制相比并不改善死亡或严重并发症风险。 实验随机选取了987名怀孕女性,其中大多数产前患有高血压。严格控制血压组的妊娠损伤或需要48小时以上新生儿高级护理的比例为30.7%,非严格控制血压的比例为31.4%。两组严重高血压比例分别为27.5%和40.6%。 受试者未用降压药时舒张压为90-105 mmHg或用药后舒张压为8

Eur Heart J:添加奥美沙坦对高血压心衰患者有害无益

日本一项研究表明,在接受循证治疗的高血压慢性心衰(CHF)患者中,添加奥美沙坦治疗未能改善临床转归,反而使肾功能恶化,尤其是奥美沙坦、肾素血管紧张素转换酶抑制剂(ACEI)和β受体阻滞剂联合治疗时与不良心脏事件增加相关。论文1月31日在线发表于《欧洲心脏杂志》(Eur Heart J)。 此项前瞻性、随机、开放标签研究共纳入1147例伴有症状性CHF的高血压患者,并在基线治疗的基础上随机